Aptose Biosciences Inc.
APS.TO
TSX
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 23.57% | -6.58% | -12.19% | -33.93% | -24.24% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -5.77% | -44.05% | -81.97% | -40.37% | -49.18% |
| Operating Income | 5.77% | 44.05% | 81.97% | 40.37% | 49.18% |
| Income Before Tax | 2.88% | 42.50% | 86.74% | 39.26% | 48.67% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 2.88% | 42.50% | 86.74% | 39.26% | 48.67% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 2.88% | 42.50% | 86.74% | 39.26% | 48.67% |
| EBIT | 5.77% | 44.05% | 81.97% | 40.37% | 49.18% |
| EBITDA | 5.72% | 43.99% | 81.97% | 40.31% | 49.15% |
| EPS Basic | 78.75% | 88.16% | 97.07% | 78.74% | 80.90% |
| Normalized Basic EPS | 78.75% | 88.16% | 97.07% | 78.74% | 80.90% |
| EPS Diluted | 78.75% | 88.16% | 97.07% | 78.74% | 80.90% |
| Normalized Diluted EPS | 78.75% | 88.16% | 97.07% | 78.74% | 80.90% |
| Average Basic Shares Outstanding | 357.01% | 385.68% | 353.23% | 185.77% | 168.77% |
| Average Diluted Shares Outstanding | 357.01% | 385.68% | 353.23% | 185.77% | 168.77% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |